今日早盘,康宁杰瑞制药-B(09966.HK)股价出现大幅波动,截至9:34,股价大跌6.78%,报4.48港元。
康宁杰瑞制药是一家生物制药公司,专注于研发、生产和商业化创新肿瘤免疫生物大分子靶向药物。公司近期与石药集团就JSKN003药物在中国内地开发及商业化达成合作,或引发股价异动。
分析人士指出,中国市场是康宁杰瑞的重要市场,合作开发新药或引起投资者对公司前景的不同判断,进而影响股价表现。不过目前尚不清楚公司最新药物合作进展是否是本次股价大跌的主因。此外,该股机构评级较为看好,100%给予"买入"评级。所在生物技术行业今日整体下跌1.44%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.